Get the Stockscreener App
8.94
0.56%
-0.05
After Hours:
9.10
0.16
+1.79%
Ocular Therapeutix Inc stock is traded at $8.94, with a volume of 2.33M.
It is down -0.56% in the last 24 hours and down -2.40% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$8.99
Open:
$8.99
24h Volume:
2.33M
Relative Volume:
0.76
Market Cap:
$1.96B
Revenue:
$52.04M
Net Income/Loss:
$-290.50M
P/E Ratio:
-6.1414
EPS:
-1.4557
Net Cash Flow:
$-240.94M
1W Performance:
+5.55%
1M Performance:
-2.40%
6M Performance:
-37.87%
1Y Performance:
+2.17%
1-Day Range:
$8.67
$9.105
1-Week Range:
$8.255
$9.255
52-Week Range:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.94 | 1.97B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-15-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan - Investing.com Nigeria
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan By Investing.com - Investing.com South Africa
Director at Ocular Therapeutix (OCUL) receives RSUs and stock options - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and options in new equity awards - Stock Titan
Ocular Therapeutix (OCUL) CFO awarded RSUs and stock options in new equity grant - Stock Titan
Ocular Therapeutix (OCUL) director receives 14,000 RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) director receives RSU and option grants - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (OCUL) director receives new RSU and stock option awards - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) expands stock plan and names new CFO - Stock Titan
Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Ocular Therapeutix Inc Annual Shareholders Meeting Transcript - GuruFocus
OCUL Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock HigherGuidance vs Actual - newsline.com
Ocular Therapeutix (OCUL) Edges Lower, Testing Key Support ZoneStandard Deviation - newsline.com
(OCUL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares - Investing.com UK
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares By Investing.com - Investing.com South Africa
Ocular Therapeutix (OCUL) CMO auto-sells 14,828 shares for taxes - Stock Titan
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Yahoo Finance
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Ocular Therapeutix, Inc. to Participate in Clinical Trials at the Summit 2026 in Las Vegas - Quiver Quantitative
Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026 - The Manila Times
Ocular Therapeutix to detail OTX-TKI trial outcomes at Vegas retina summit - Stock Titan
OCUL (NASDAQ: OCUL) Form 144 — 14,828 restricted shares vesting - Stock Titan
OCUL Technical Analysis | Trend, Signals & Chart Patterns | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Host Investor Day on June 17, 2026 - GlobeNewswire
Ocular Therapeutix (OCUL) Valuation Check After Recent Trading And AXPAXLI Growth Expectations - Sahm
Ocular Therapeutix Stock Hits Day High with Strong 7.14% Intraday Surge - Markets Mojo
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix CDO Peter Kaiser sells $24,329 in stock By Investing.com - Investing.com India
Ocular Therapeutix chief scientific officer sells $24,747 in stock By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief scientific officer sells $24,747 in stock - Investing.com
Ocular Therapeutix CDO Peter Kaiser sells $24,329 in stock - Investing.com
Liquidity Mapping Around (OCUL) Price Events - Stock Traders Daily
Automatic tax-driven sale and trust transfer by Ocular (OCUL) insider - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) CDO executes 2,967-share tax sell-to-cover trade - Stock Titan
Ocular Therapeutix (OCUL) CSO sells 3,018 shares to cover RSU taxes - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) CSO auto-sells 1,858 shares for tax obligations - Stock Titan
Ocular Therapeutix, Inc. (OCUL) Latest Stock News & Headlines - Yahoo Finance
OCUL Q1 2026 Earnings: Wider-than-Expected Loss but Stock Gains on Pipeline ProgressLow Estimate Range - newsline.com
Ocular Therapeutix (OCUL) Rises 3% as Investor Sentiment StrengthensBear Flag - newsline.com
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 - The Motley Fool
Morgan Stanley (NASDAQ: OCUL) files Rule 144 notice to sell 1,858 shares - Stock Titan
Company (NASDAQ: OCUL) files Form 144 to sell 2,967 shares - Stock Titan
OCUL (NASDAQ: OCUL) files Form 144 proposing sale of 3,018 shares - Stock Titan
Rule 144 notice for 21,156 shares — OCUL (OCUL) - Stock Titan
Ocular Therapeutix Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):